定量影像生物标志物联盟(QIBA)关于提高多中心肿瘤试验中DWI和DCE-MRI衍生生物标志物精度的建议
本文综述了肿瘤扩散加权成像和动态增强MRI衍生定量影像生物标志物(QIB)在肿瘤应用中的需求,强调评估其可重复性和重现性的重要性,并介绍了QIBA和QIN在提供技术性能标准(QIBA profiles)和工具方面的目标与使命,指出QIB文献缺乏且与MRI技术进展不同步。
要点
- 肿瘤DWI和DCE-MRI衍生的定量影像生物标志物需标准化采集和体模验证。
- QIBA旨在提供技术性能标准(profiles)和QIN工具以产生可靠的QIB。
- QIB的可重复性和重现性文献缺乏,阻碍了DWI和DCE-MRI QIB profiles的发展。
核心结论
- 肿瘤DWI和DCE-MRI衍生的QIB在临床 trials 和实践中转化需要标准化采集和评估可重复性与重现性,但现有文献缺乏且与MRI技术进步不同步。
研究设计与样本
- 综述;检索范围与纳入文献原文未报告;证据等级5,技术效能阶段1。
诊断标准与关键数值
- QIBA定义的QIB需满足技术性能标准(QIBA profiles),但原文未给出具体敏感度、特异度、AUC或阈值。
临床应用与阅片要点
- 使用适当的体模标准化图像采集是技术性能评估的第一步。
- 需评估成像指标是否具有临床价值并符合QIBA对QIB的要求。
- QIBA和QIN旨在为临床影像社区提供可靠QIB的技术性能标准和工具。
局限性
- 缺乏关于衍生QIB可重复性和重现性的文献。
- 现有研究稀少且与多年来MRI技术的改进或升级不同步。
- QIBA定量DWI和DCE-MRI QIB profiles的部分开发因缺乏可重复性和重现性文献而受阻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Physiological properties of tumors can be measured both in vivo and noninvasively by diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging. Although these techniques have been used for more than two decades to study tumor diffusion, perfusion, and/or permeability, the methods and studies on how to reduce measurement error and bias in the derived imaging metrics is still lacking in the literature. This is of paramount importance because the objective is to translate these quantitative imaging biomarkers (QIBs) into clinical trials, and ultimately in clinical practice. Standardization of the image acquisition using appropriate phantoms is the first step from a technical performance standpoint. The next step is to assess whether the imaging metrics have clinical value and meet the requirements for being a QIB as defined by the Radiological Society of North America's Quantitative Imaging Biomarkers Alliance (QIBA). The goal and mission of QIBA and the National Cancer Institute Quantitative Imaging Network (QIN) initiatives are to provide technical performance standards (QIBA profiles) and QIN tools for producing reliable QIBs for use in the clinical imaging community. Some of QIBA's development of quantitative diffusion-weighted imaging and dynamic contrast-enhanced QIB profiles has been hampered by the lack of literature for repeatability and reproducibility of the derived QIBs. The available research on this topic is scant and is not in sync with improvements or upgrades in MRI technology over the years. This review focuses on the need for QIBs in oncology applications and emphasizes the importance of the assessment of their reproducibility and repeatability. Level of Evidence: 5 Technical Efficacy Stage: 1 J. Magn. Reson. Imaging 2019;49:e101-e121.
引用
- Shukla-Dave A, Obuchowski NA, Chenevert TL, et al. Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. J Magn Reson Imaging. 2018. PMID: 30451345. doi:10.1002/jmri.26518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。